Logo image of RYTM

RHYTHM PHARMACEUTICALS INC (RYTM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RYTM - US76243J1051 - Common Stock

107.04 USD
+0.28 (+0.26%)
Last: 12/31/2025, 4:51:37 PM
107.04 USD
0 (0%)
After Hours: 12/31/2025, 4:51:37 PM
Fundamental Rating

4

Taking everything into account, RYTM scores 4 out of 10 in our fundamental rating. RYTM was compared to 530 industry peers in the Biotechnology industry. While RYTM seems to be doing ok healthwise, there are quite some concerns on its profitability. RYTM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RYTM has reported negative net income.
In the past year RYTM has reported a negative cash flow from operations.
RYTM had negative earnings in each of the past 5 years.
In the past 5 years RYTM always reported negative operating cash flow.
RYTM Yearly Net Income VS EBIT VS OCF VS FCFRYTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

RYTM has a Return On Assets (-39.01%) which is in line with its industry peers.
The Return On Equity of RYTM (-66.87%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -39.01%
ROE -66.87%
ROIC N/A
ROA(3y)-56.77%
ROA(5y)-52.61%
ROE(3y)-112.7%
ROE(5y)-88.62%
ROIC(3y)N/A
ROIC(5y)N/A
RYTM Yearly ROA, ROE, ROICRYTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Gross Margin of RYTM (89.40%) is better than 91.51% of its industry peers.
In the last couple of years the Gross Margin of RYTM has grown nicely.
The Profit Margin and Operating Margin are not available for RYTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.35%
GM growth 5YN/A
RYTM Yearly Profit, Operating, Gross MarginsRYTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RYTM has more shares outstanding
The number of shares outstanding for RYTM has been increased compared to 5 years ago.
Compared to 1 year ago, RYTM has an improved debt to assets ratio.
RYTM Yearly Shares OutstandingRYTM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RYTM Yearly Total Debt VS Total AssetsRYTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

RYTM has an Altman-Z score of 16.70. This indicates that RYTM is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 16.70, RYTM belongs to the best of the industry, outperforming 86.79% of the companies in the same industry.
A Debt/Equity ratio of 0.35 indicates that RYTM is not too dependend on debt financing.
RYTM has a worse Debt to Equity ratio (0.35) than 70.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z 16.7
ROIC/WACCN/A
WACC8.71%
RYTM Yearly LT Debt VS Equity VS FCFRYTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.75 indicates that RYTM has no problem at all paying its short term obligations.
With a Current ratio value of 4.75, RYTM perfoms like the industry average, outperforming 55.28% of the companies in the same industry.
RYTM has a Quick Ratio of 4.53. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.53, RYTM perfoms like the industry average, outperforming 54.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.75
Quick Ratio 4.53
RYTM Yearly Current Assets VS Current LiabilitesRYTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.65% over the past year.
RYTM shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.88%.
RYTM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 245.69% yearly.
EPS 1Y (TTM)30.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.33%
Revenue 1Y (TTM)25.88%
Revenue growth 3Y245.69%
Revenue growth 5YN/A
Sales Q2Q%54.28%

3.2 Future

RYTM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.64% yearly.
The Revenue is expected to grow by 63.37% on average over the next years. This is a very strong growth
EPS Next Y27.27%
EPS Next 2Y17.77%
EPS Next 3Y26.76%
EPS Next 5Y32.64%
Revenue Next Year48.07%
Revenue Next 2Y51.96%
Revenue Next 3Y61.88%
Revenue Next 5Y63.37%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RYTM Yearly Revenue VS EstimatesRYTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
RYTM Yearly EPS VS EstimatesRYTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RYTM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RYTM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RYTM Price Earnings VS Forward Price EarningsRYTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RYTM Per share dataRYTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

RYTM's earnings are expected to grow with 26.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.77%
EPS Next 3Y26.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RYTM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

RHYTHM PHARMACEUTICALS INC

NASDAQ:RYTM (12/31/2025, 4:51:37 PM)

After market: 107.04 0 (0%)

107.04

+0.28 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners105.14%
Inst Owner Change9.07%
Ins Owners0.66%
Ins Owner Change0.13%
Market Cap7.14B
Revenue(TTM)174.33M
Net Income(TTM)-197.71M
Analysts85.71
Price Target138.45 (29.34%)
Short Float %8.77%
Short Ratio7.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.95%
Min EPS beat(2)-11.05%
Max EPS beat(2)-8.85%
EPS beat(4)1
Avg EPS beat(4)-8.08%
Min EPS beat(4)-13.18%
Max EPS beat(4)0.76%
EPS beat(8)4
Avg EPS beat(8)-2.62%
EPS beat(12)6
Avg EPS beat(12)-1.12%
EPS beat(16)9
Avg EPS beat(16)1.52%
Revenue beat(2)1
Avg Revenue beat(2)4.08%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.98%
Revenue beat(4)2
Avg Revenue beat(4)-1.44%
Min Revenue beat(4)-20.47%
Max Revenue beat(4)8.98%
Revenue beat(8)3
Avg Revenue beat(8)-2.28%
Revenue beat(12)5
Avg Revenue beat(12)1.84%
Revenue beat(16)7
Avg Revenue beat(16)13.94%
PT rev (1m)8.46%
PT rev (3m)20.65%
EPS NQ rev (1m)-3.94%
EPS NQ rev (3m)-14.87%
EPS NY rev (1m)-6.51%
EPS NY rev (3m)-6.33%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)0.69%
Revenue NY rev (1m)0.85%
Revenue NY rev (3m)0.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.98
P/FCF N/A
P/OCF N/A
P/B 24.16
P/tB 24.62
EV/EBITDA N/A
EPS(TTM)-3.1
EYN/A
EPS(NY)-2.75
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS2.61
BVpS4.43
TBVpS4.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.01%
ROE -66.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.4%
FCFM N/A
ROA(3y)-56.77%
ROA(5y)-52.61%
ROE(3y)-112.7%
ROE(5y)-88.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.35%
GM growth 5YN/A
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.75
Quick Ratio 4.53
Altman-Z 16.7
F-Score5
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.33%
EPS Next Y27.27%
EPS Next 2Y17.77%
EPS Next 3Y26.76%
EPS Next 5Y32.64%
Revenue 1Y (TTM)25.88%
Revenue growth 3Y245.69%
Revenue growth 5YN/A
Sales Q2Q%54.28%
Revenue Next Year48.07%
Revenue Next 2Y51.96%
Revenue Next 3Y61.88%
Revenue Next 5Y63.37%
EBIT growth 1Y54.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.12%
EBIT Next 3Y26.77%
EBIT Next 5YN/A
FCF growth 1Y22.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.48%
OCF growth 3YN/A
OCF growth 5YN/A

RHYTHM PHARMACEUTICALS INC / RYTM FAQ

What is the fundamental rating for RYTM stock?

ChartMill assigns a fundamental rating of 4 / 10 to RYTM.


What is the valuation status of RHYTHM PHARMACEUTICALS INC (RYTM) stock?

ChartMill assigns a valuation rating of 1 / 10 to RHYTHM PHARMACEUTICALS INC (RYTM). This can be considered as Overvalued.


How profitable is RHYTHM PHARMACEUTICALS INC (RYTM) stock?

RHYTHM PHARMACEUTICALS INC (RYTM) has a profitability rating of 2 / 10.


How financially healthy is RHYTHM PHARMACEUTICALS INC?

The financial health rating of RHYTHM PHARMACEUTICALS INC (RYTM) is 5 / 10.


Can you provide the expected EPS growth for RYTM stock?

The Earnings per Share (EPS) of RHYTHM PHARMACEUTICALS INC (RYTM) is expected to grow by 27.27% in the next year.